AtriCure to Participate at the Canaccord 41st Annual Growth Conference

Rhea-AI Summary

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), has announced its participation in the Canaccord 41^st Annual Growth Conference. The company will present on August 11, 2021, at 8:00 a.m. Eastern Time. Interested participants can access the live and archived audio webcast on AtriCure’s website. AtriCure is known for its innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® for left atrial appendage management, addressing the needs of over 33 million Afib sufferers globally.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41^st Annual Growth Conference.

AtriCure’s management is scheduled to present on Wednesday, August 11, 2021, at 8:00 a.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF^TM Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE^® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210730005031/en/

FAQ

When is AtriCure's presentation at the Canaccord 41st Annual Growth Conference?

AtriCure's presentation is scheduled for August 11, 2021, at 8:00 a.m. Eastern Time.

How can I listen to AtriCure's presentation at the conference?

You can access the live and archived audio webcast of AtriCure's presentation on their website in the 'Investors' section.

What is AtriCure known for in the medical field?

AtriCure is recognized for its innovative technologies in the treatment of atrial fibrillation and related conditions.

What is the significance of the Isolator® Synergy™ Ablation System?

The Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for treating persistent atrial fibrillation.

How many people are affected by atrial fibrillation globally?

Atrial fibrillation affects more than 33 million people worldwide.